ANALYST-UPGRADE ·Filed Oct 12, 2026
JP Morgan double upgrade: Neutral → Overweight
Latest settled — T+1d
BIIB ▼ -0.22% at T+1d
LONG call ✗ call lost -0.22% · α vs SPY -0.21% · entry $229.41 → $228.90
T+1d
-0.22%
call -0.22% · α -0.21%
$228.90
settled 6d ago
T+5d
—
call — · α —
—
in 5h
T+20d
—
call — · α —
—
in 21d
T+60d
—
call — · α —
—
in 3mo
Price Chart
Loading chart...
Executive Summary
JP Morgan double upgrade: Neutral → Overweight
Impact Score
Base Score
4/7
LLM Adjustment
+0
Final Score
4/10
Consensus & Targets
Buy / Strong Buy
30 (70%)
Hold
12
Sell / Strong Sell
1
Total Analysts
31
Mean PT
$238.18
Median PT
$240.00
High PT
$300.00
Low PT
$175.00
Current Price
$223.59
Implied Upside
+6.5%
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-12 | JP Morgan | upgrade | Overweight | $300.00 |
| 2026-10-09 | UBS | maintain | Buy | $270.00 |
| 2026-10-08 | RBC Capital | maintain | Outperform | $256.00 |
| 2026-09-10 | HSBC | maintain | Reduce | $175.00 |
| 2026-09-03 | Piper Sandler | reiterate | Overweight | $245.00 |
| 2026-08-25 | RBC Capital | maintain | Outperform | $260.00 |
| 2026-08-13 | Wolfe Research | upgrade | Outperform | $300.00 |
| 2026-08-04 | Mizuho | maintain | Outperform | $241.00 |
| 2026-08-03 | Citigroup | maintain | Neutral | — |
| 2026-07-30 | UBS | maintain | Buy | $240.00 |
Firm Track Record — JP Morgan
JP Morgan accuracy: 55% on 5699 calls | avg return: 5.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 13% | top tier |
| Morgan Stanley | 83% | 5/6 | 5.5% | top tier |
| Piper Sandler | 71% | 5/7 | 1.6% | top tier |
| Wedbush | 67% | 4/6 | 2.1% | top tier |
| JP Morgan | 67% | 2/3 | 2.5% | top tier |
| HC Wainwright & Co. | 57% | 4/7 | 1.4% | above average |
| UBS | 50% | 1/2 | 0.6% | below average |
| Barclays | 50% | 2/4 | -2.8% | below average |
| Canaccord Genuity | 50% | 1/2 | -2.1% | below average |
| Goldman Sachs | 50% | 1/2 | -0.1% | below average |
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $12.54 | $12.00 — $16.39 | $10.4B | ↑0 ↓0 |
| +1q | $3.27 | $2.77 — $3.87 | $2.6B | ↑0 ↓0 |
| 0q | $2.03 | $1.44 — $2.67 | $2.6B | ↑0 ↓0 |
| +1y | $16.54 | $13.33 — $19.29 | $10.7B | ↑0 ↓0 |
Cross-Platform Signals
Insider Trades (90d)
0 buys / 2 sells
Congressional
Kevin Hern (republican) — sell $1,001 - $15,000
Institutional
QRG CAPITAL MANAGEMENT, INC. — add (47.9%)
Institutional
CITADEL ADVISORS LLC — doubled (203%)
Institutional
Amundi — add (91.8%)
Short Interest
Short: 315,067 | Exempt: 0 | TRF Vol: 501,596 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
Report based on filing metadata.
26 reports for BIIB
92% Hit rate best @ T+60▲ +15.73%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $229.41 $228.90 | ▼ −0.22% | ▼ −0.21% | $232.65 (+1.41%) |
Sep 3, 2026 6w ago | Press Release | $220.83 $212.50 | ▼ −3.77% | ▼ −3.22% | $232.65 (+5.35%) |
Sep 3, 2026 6w ago | Press Release | $224.51 $220.83 | ▼ −1.64% | ▼ −1.25% | $232.65 (+3.63%) |
Aug 6, 2026 10w ago | Press Release | $207.94 $207.13 | ▼ −0.39% | ▼ −0.36% | $232.65 (+11.88%) |
Jul 14, 2026 13w ago | Press Release | $191.95 $197.24 | ▲ +2.76% | ▲ +2.36% | $232.65 (+21.20%) |
Jul 13, 2026 13w ago | Press Release | $191.95 $197.24 | ▲ +2.76% | ▲ +2.36% | $232.65 (+21.20%) |
Jul 13, 2026 13w ago | ANALYST-UPGRADE | — | awaiting T+1 | — | — |
Jun 17, 2026 17w ago | Press Release | $196.58 $199.71 | ▲ +1.59% | ▲ +1.91% | $232.65 (+18.35%) |
Jun 8, 2026 18w ago | ANALYST-UPGRADE | $192.62 $199.10 | ▲ +3.36% | ▲ +3.66% | $232.65 (+20.78%) |
Jun 4, 2026 19w ago | Press Release | $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $232.65 (+18.81%) |
Showing 10 of 26
US Market Status
Market Closed — Opens in 6h 34m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access